You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco, CA, along with the invaluable expertise provided by Astellas to advance...
CRESEMBA is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections Approval based on results of two...
GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States1,2 Eric and his mother, Jamey, are...
If approved, CRESEMBA will offer a new treatment option for pediatric patients facing certain invasive fungal infections NORTHBROOK, Ill., Aug. 10, 2023 /PRNewswire/ -- Astellas Pharma US, Inc....
Read more about U.S. FDA Accepts Astellas' sNDA for CRESEMBA® (isavuconazonium sulfate) in Children
Both Companies win a year of access to a prestigious life-science incubator in San Francisco, CA and to Astellas expertise to further their research Award helps biotech start-ups accelerate early...
Follow U.S. news
